Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye

被引:30
作者
Vaajanen, Anu [1 ]
Vapaatalo, Heikki [1 ]
Kautiainen, Hannu [2 ]
Oksala, Olli [3 ]
机构
[1] Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland
[2] Rheumatism Fdn Hosp, SF-18120 Heinola, Finland
[3] Santen Oy, Div Res & Dev, Tampere, Finland
关键词
D O I
10.1167/iovs.07-1399
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. In the present study the effects of exogenous angiotensin II and its breakdown metabolite angiotensin (1-7) on the intraocular pressure (IOP) and on aqueous humor dynamics in normotensive rabbit eye were evaluated. METHODS. Male New Zealand White rabbits with normal IOP were used for intravitreous and topical administration of the test compounds. IOP was measured in conscious rabbits by pneumatonometer after topical anesthesia. Outflow measurements were made with a two-level constant pressure method in anesthetized animals. RESULTS. Angiotensin (1-7) administered intravitreously reduced IOP within 1 to 5 hours (P < 0.05). This effect was abolished by the selective angiotensin (1-7) antagonist A-779, and partially by the selective angiotensin II type 2 receptor antagonist PD123319. When olmesartan, an angiotensin II type 1 receptor blocker, was administered simultaneously with angiotensin (1-7), no antagonism was seen. Intravitreous administration of CGP42112 A, an angiotensin II type 2 receptor agonist, and angiotensin II did not significantly influence IOP, nor did topical administration of these compounds alter IOP. Angiotensin II significantly reduced outflow facility (P < 0.01) dose dependently, whereas angiotensin (1-7) had no effect. CONCLUSIONS. Angiotensin (1-7) is a biologically active vasodilatory and antiproliferative heptapeptide, and its vascular effects counteract those of angiotensin II. It reduces intraocular pressure possibly by a selective Mas receptor, without changing aqueous humor outflow facility in the normotensive rabbit eye.
引用
收藏
页码:2557 / 2562
页数:6
相关论文
共 47 条
[1]   Effect of simultaneous CGRP and PGF2a on the outflow facility in the rabbit eye [J].
Alajuuma, P ;
Oksala, O ;
Alaranta, S ;
Palkama, A ;
Uusitalo, H .
OPHTHALMIC RESEARCH, 2002, 34 (05) :309-313
[2]  
BARANY EH, 1964, INVEST OPHTH VISUAL, V3, P135
[3]   Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide [J].
Brosnihan, KB ;
Li, P ;
Ferrario, CM .
HYPERTENSION, 1996, 27 (03) :523-528
[4]   Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation [J].
Carey, RM ;
Siragy, HM .
ENDOCRINE REVIEWS, 2003, 24 (03) :261-271
[5]   Metabolism of angiotension-(1-7) by angiotensin-converting enzyme [J].
Chappell, MC ;
Pirro, NT ;
Sykes, A ;
Ferrario, CM .
HYPERTENSION, 1998, 31 (01) :362-367
[6]   USE OF AN ANGIOTENSIN CONVERTING ENZYME-INHIBITOR IN OCULAR HYPERTENSION AND PRIMARY OPEN-ANGLE GLAUCOMA [J].
CONSTAD, WH ;
FIORE, P ;
SAMSON, C ;
CINOTTI, AA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1988, 105 (06) :674-677
[7]   Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects [J].
Costagliola, C ;
Verolino, M ;
De Rosa, ML ;
Iaccarino, G ;
Ciancaglini, M ;
Mastropasqua, L .
EXPERIMENTAL EYE RESEARCH, 2000, 71 (02) :167-171
[8]   Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium [J].
Cullinane, AB ;
Leung, PS ;
Ortego, J ;
Coca-Prados, M ;
Harvey, BJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2002, 86 (06) :676-683
[9]   BLOOD-OCULAR BARRIERS [J].
CUNHAVAZ, J .
SURVEY OF OPHTHALMOLOGY, 1979, 23 (05) :279-296
[10]   RENIN, PRORENIN, AND IMMUNOREACTIVE RENIN IN VITREOUS FLUID FROM EYES WITH AND WITHOUT DIABETIC-RETINOPATHY [J].
DANSER, AHJ ;
VANDENDORPEL, MA ;
DEINUM, J ;
DERKX, FHM ;
FRANKEN, AAM ;
PEPERKAMP, E ;
DEJONG, PTVM ;
SCHALEKAMP, MADH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (01) :160-167